Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PBYI
STRONG BUYPuma Biotechnology, Inc. · Healthcare · United States · $413M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products for the treatment of cancer. Its lead product, Nerlynx, is approved for certain types of early-stage HER2-positive breast cancer. The company's competitive position is anchored by its approved oncology therapeutic and ongoing clinical development pipeline, operating in the high-stakes pharmaceutical market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 228.0M | 235.6M | 230.5M | 228.4M | 0.0% | 227.2M | 222.0M | 219.0M | -2.1% |
| EPS | 0.00 | 0.46 | 0.62 | 0.62 | 16.1% | 0.48 | 0.37 | — | -40.0% |
| Shares | 46.3M | 47.6M | 49.1M | 50.4M | +8.8% | 50.9M | — | — | — |
| Debt | 114.3M | 111.5M | 74.1M | 28.5M | -37.0% | 16.0M | — | — | — |
| Equity | 21.6M | 53.4M | 92.1M | 130.3M | 82.0% | — | — | — | — |
| Op CF | -15.8M | 27.0M | 38.9M | 41.8M | 24.4% | 53.6M | — | — | — |
| Inv CF | 7.1M | -19.1M | -20.4M | -36.2M | — | — | — | — | — |
| Fin CF | 12.2M | 0 | -33.8M | -45.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBYI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PBYI | Puma Biotechnology, Inc.(you) | $413M | 98 | STRONG BUY |
| CRMD | CorMedix Inc. | $616M | 96 | STRONG BUY |
| RIGL | Rigel Pharmaceuticals, Inc. | $716M | 98 | STRONG BUY |
| ZVRA | Zevra Therapeutics, Inc. | $799M | 90 | STRONG BUY |
| MDXG | MiMedx Group, Inc. | $585M | 77 | BUY |
| INVA | Innoviva, Inc. | $1.7B | 97 | STRONG BUY |
| ABUS | Arbutus Biopharma Corporation | $905M | 84 | STRONG BUY |
| NAGE | Niagen Bioscience, Inc. | $272M | 75 | BUY |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.1B | 99 | STRONG BUY |
| ABEO | Abeona Therapeutics Inc. | $320M | 64 | HOLD |
Peer medians: ROE -21.3% · P/E 27.3x · Gross margin 44.3%